Cytokine signaling receptors cross-reactivity

GA, administered subcutaneously to patients with relapsing-remitting MS, decreased the rate of exacerbations by -30%. In vivo administration of GA induces highly cross-reactive CD4+ T cells that are immune-deviated to secrete Th2 cytokines and prevents the appearance of new lesions detectable by MRI. This represents one of the first successful uses of an agent that ameliorates autoimmune disease by altering signals through the T-ceU receptor complex. 

---